$AYTU
AYTU BIOPHARMA, INC Stock $aytu

$aytu Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000143774921012543 Filed on May 17, 2021

Income Statement

Concept	2021 Q2	2021 Q1	2020 Q2
Revenue	$23.48M	$13.48M	$14.86M
YoY Change	58.02%	65.3%	763.95%
Cost Of Revenue	$12.93M	$13.94M	$4.570M
YoY Change	182.98%	597.22%	603.08%
Gross Profit	$10.55M	-$452.0K	$10.29M
YoY Change	2.53%	-107.34%	861.68%
Gross Profit Margin	44.93%	-3.35%	69.25%
Selling, General & Admin	$19.98M	$12.85M	$13.64M
YoY Change	46.5%	39.83%	178.37%
% of Gross Profit	189.41%		132.56%
Research & Development	$4.764M	$390.0K	$1.500M
YoY Change	217.62%	396.8%	733.33%
% of Gross Profit	45.16%		14.58%
Depreciation & Amortization	-$1.099M	$100.0K	$2.470M
YoY Change	-144.49%	-93.83%	225.0%
% of Gross Profit	-10.42%		24.0%
Operating Expenses	$21.72M	$25.21M	$16.73M
YoY Change	29.81%	172.03%	196.11%
Operating Profit	-$11.17M	-$25.67M	-$6.440M
YoY Change	73.39%	435.44%	40.61%
Interest Expense	-$494.1K	-$425.4K	-$1.430M
YoY Change	-65.45%	-21.05%	1091.67%
% of Operating Profit
Other Income/Expense, Net	$7.139M	$206.0K
YoY Change		-138.23%
Pretax Income	-$18.74M	-$25.46M	-$3.150M
YoY Change	494.89%	377.67%	-78.32%
Income Tax	$259.0K
% Of Pretax Income
Net Earnings	-$19.00M	-$25.46M	-$3.150M
YoY Change	503.11%	377.47%	-78.32%
Net Earnings / Revenue	-80.9%	-188.84%	-21.2%
Basic Earnings Per Share		-$1.41
Diluted Earnings Per Share	-$807.9K	-$1.41	-$279.0K
COMMON SHARES
Basic Shares Outstanding	25.17M	18.09M
Diluted Shares Outstanding		18.09M

Balance Sheet

Concept	2021 Q2	2021 Q1	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.65M	$46.50M	$48.10M
YoY Change	3.22%	-25.36%	337.27%
Cash & Equivalents	$49.65M	$46.54M	$48.08M
Short-Term Investments
Other Short-Term Assets	$1.038M	$1.615M	$5.742M
YoY Change	-81.92%	-76.59%	341.69%
Inventory	$16.34M	$16.58M	$9.999M
Prepaid Expenses	$9.780M		$5.715M
Receivables	$28.18M	$28.23M	$5.633M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$105.2M	$100.0M	$75.42M
YoY Change	39.53%	20.06%	389.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.703M	$5.558M	$258.5K
YoY Change	3266.52%	455.77%	29.26%
Goodwill	$65.80M	$65.80M	$28.09M
YoY Change	134.25%
Intangibles	$85.46M	$96.24M	$48.86M
YoY Change	74.93%
Long-Term Investments
YoY Change
Other Assets	$465.0K	$165.0K	$33.00K
YoY Change	1309.09%
Total Long-Term Assets	$160.4M	$171.5M	$77.87M
YoY Change	106.03%	126.61%	303.48%
TOTAL ASSETS
Total Short-Term Assets	$105.2M	$100.0M	$75.42M
Total Long-Term Assets	$160.4M	$171.5M	$77.87M
Total Assets	$265.7M	$271.6M	$153.3M
YoY Change	73.31%	70.79%	341.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.26M	$16.53M	$11.64M
YoY Change	65.42%	55.93%	406.09%
Accrued Expenses	$51.30M	$43.18M	$8.831M
YoY Change	480.85%	296.16%	341.55%
Deferred Revenue	$200.0K		$339.3K
YoY Change	-41.06%
Short-Term Debt	$7.934M	$4.700M	$0.00
YoY Change
Long-Term Debt Due	$16.67M	$700.0K	$0.00
YoY Change
Total Short-Term Liabilities	$109.4M	$83.68M	$28.76M
YoY Change	280.48%	99.25%	432.65%
LONG-TERM LIABILITIES
Long-Term Debt	$180.0K	$16.90M	$0.00
YoY Change
Other Long-Term Liabilities	$355.0K	$92.89K	$11.00K
YoY Change	3127.27%	-99.7%	-99.95%
Total Long-Term Liabilities	$355.0K	$92.89K	$11.00K
YoY Change	3127.27%	-99.7%	-99.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$109.4M	$83.68M	$28.76M
Total Long-Term Liabilities	$355.0K	$92.89K	$11.00K
Total Liabilities	$128.1M	$128.4M	$58.28M
YoY Change	119.81%	75.42%	111.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$178.3M	-$159.3M	-$120.0M
YoY Change	48.58%
Common Stock	$315.9M	$2.346K	$1.000K
YoY Change	31586600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$137.6M	$143.2M	$95.02M
YoY Change
Total Liabilities & Shareholders Equity	$265.7M	$271.6M	$153.3M
YoY Change	73.31%	70.79%	341.77%

Cashflow Statement

Concept	2021 Q2	2021 Q1	2020 Q2
OPERATING ACTIVITIES
Net Income	-$19.00M	-$25.46M	-$3.150M
YoY Change	503.11%	377.47%	-78.32%
Depreciation, Depletion And Amortization	-$1.099M	$100.0K	$2.470M
YoY Change	-144.49%	-93.83%	225.0%
Cash From Operating Activities	-$6.284M	$19.70M	-$7.760M
YoY Change	-19.02%	-4.37%	123.63%
INVESTING ACTIVITIES
Capital Expenditures	-$2.341M		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$81.00K	-$310.0K	-$50.00K
YoY Change	62.0%	-191.18%	-44.44%
Cash From Investing Activities	-$2.422M	-$310.0K	-$50.00K
YoY Change	4744.0%	-191.18%	-44.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.81M	-6.400M	-6.370M
YoY Change	-285.46%	-109.39%	-5408.33%
NET CHANGE
Cash From Operating Activities	-6.284M	19.70M	-7.760M
Cash From Investing Activities	-2.422M	-310.0K	-50.00K
Cash From Financing Activities	11.81M	-6.400M	-6.370M
Net Change In Cash	3.108M	19.70M	-14.18M
YoY Change	-121.92%	-4.37%	312.21%
FREE CASH FLOW
Cash From Operating Activities	-$6.284M	$19.70M	-$7.760M
Capital Expenditures	-$2.341M		$0.00
Free Cash Flow	-$3.943M		-$7.760M
YoY Change	-49.19%		123.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q1	aytu	Accrued Distributor Fees AccruedDistributorFees	2816000
CY2020Q2	aytu	Accrued Distributor Fees AccruedDistributorFees	457000
CY2021Q1	aytu	Accrued Productrelated Fees AccruedProductrelatedFees	2379000
CY2020Q2	aytu	Accrued Productrelated Fees AccruedProductrelatedFees	2471000
CY2021Q1	aytu	Accrued Program Related Liabilities AccruedProgramRelatedLiabilities	7836000
CY2020Q2	aytu	Accrued Program Related Liabilities AccruedProgramRelatedLiabilities	959000
CY2021Q1	aytu	Accrued Saving Offers AccruedSavingOffers	19218000
CY2020Q2	aytu	Accrued Saving Offers AccruedSavingOffers
CY2021Q1	aytu	Adjustments To Additional Paid In Capital Estimated Fair Value Of Replacement Equity Awards AdjustmentsToAdditionalPaidInCapitalEstimatedFairValueOfReplacementEquityAwards	432289
CY2021Q1	aytu	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	5870436
CY2020Q1	aytu	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	1370986
	aytu	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	9039597
	aytu	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	2899553
	aytu	Class Of Warrant Or Right Cancelled During Period ClassOfWarrantOrRightCancelledDuringPeriod	1434763
	aytu	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	403760
CY2020	aytu	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P2Y
	aytu	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P3Y18D
	aytu	Contingent Consideration Included In Accounts Payable ContingentConsiderationIncludedInAccountsPayable
	aytu	Contingent Consideration Included In Accounts Payable ContingentConsiderationIncludedInAccountsPayable	27571
CY2021Q1	aytu	Contingent Value Rights Liabilities Current ContingentValueRightsLiabilitiesCurrent	911826
CY2020Q2	aytu	Contingent Value Rights Liabilities Current ContingentValueRightsLiabilitiesCurrent	839734
CY2021Q1	aytu	Contingent Value Rights Liabilities Noncurrent ContingentValueRightsLiabilitiesNoncurrent	4679227
CY2020Q2	aytu	Contingent Value Rights Liabilities Noncurrent ContingentValueRightsLiabilitiesNoncurrent	4731866
	aytu	Contingent Value Rights Payout ContingentValueRightsPayout	1000000
	aytu	Contingent Value Rights Payout ContingentValueRightsPayout
CY2021Q1	aytu	Credit Card Liabilities CreditCardLiabilities	657000
CY2020Q2	aytu	Credit Card Liabilities CreditCardLiabilities	510000
	aytu	Estimated Fair Value Of Replacement Equity Awards EstimatedFairValueOfReplacementEquityAwards	432289
	aytu	Estimated Fair Value Of Replacement Equity Awards EstimatedFairValueOfReplacementEquityAwards
CY2021Q1	aytu	Medicaid Liabilities MedicaidLiabilities	1948000
CY2021Q1	aytu	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	59476500
	aytu	Fixed Payment Arrangements Included In Accrued Liabilities FixedPaymentArrangementsIncludedInAccruedLiabilities	1575000
	aytu	Fixed Payment Arrangements Included In Accrued Liabilities FixedPaymentArrangementsIncludedInAccruedLiabilities	501766
CY2021Q1	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration
CY2020Q1	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration
	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration
	aytu	Gain Loss From Derecognition Of Contingent Consideration GainLossFromDerecognitionOfContingentConsideration	5199806
	aytu	Gain Loss On Change In Fair Value Of Cvr Payout GainLossOnChangeInFairValueOfCvrPayout
	aytu	Gain Loss On Change In Fair Value Of Cvr Payout GainLossOnChangeInFairValueOfCvrPayout	267130
CY2021Q1	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt
CY2020Q1	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt
	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-257559
	aytu	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt
	aytu	Increase Decrease In Fixed Payment Arrangements IncreaseDecreaseInFixedPaymentArrangements
	aytu	Increase Decrease In Fixed Payment Arrangements IncreaseDecreaseInFixedPaymentArrangements	-657655
	aytu	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-26648
	aytu	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities
CY2021Q1	aytu	Increase Decrease In Revenues Percentage IncreaseDecreaseInRevenuesPercentage	0.65
	aytu	Increase Decrease In Revenues Percentage IncreaseDecreaseInRevenuesPercentage	2.3
	aytu	Inventory Payment Included In Accounts Payable InventoryPaymentIncludedInAccountsPayable
	aytu	Inventory Payment Included In Accounts Payable InventoryPaymentIncludedInAccountsPayable	460416
CY2020Q2	aytu	Medicaid Liabilities MedicaidLiabilities	1842000
CY2021Q1	aytu	Operating Lease And Finance Lease Liability OperatingLeaseAndFinanceLeaseLiability	4090000
CY2020Q2	aytu	Operating Lease And Finance Lease Liability OperatingLeaseAndFinanceLeaseLiability	1025000
CY2021Q1	aytu	Operating Lease And Finance Lease Rightofuse Asset OperatingLeaseAndFinanceLeaseRightofuseAsset	4129000
CY2020Q2	aytu	Operating Lease And Finance Lease Rightofuse Asset OperatingLeaseAndFinanceLeaseRightofuseAsset	634000
	aytu	Payments For Fixed Payment Arrangement PaymentsForFixedPaymentArrangement	3034093
	aytu	Payments For Fixed Payment Arrangement PaymentsForFixedPaymentArrangement
	aytu	Proceeds From Deposits Investing Activities ProceedsFromDepositsInvestingActivities	-3923
	aytu	Proceeds From Deposits Investing Activities ProceedsFromDepositsInvestingActivities
	aytu	Restricted Stock Issued During Period Value RestrictedStockIssuedDuringPeriodValue
	aytu	Restricted Stock Issued During Period Value RestrictedStockIssuedDuringPeriodValue	107
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	AYTU BIOPHARMA, INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	aytu
	aytu	Return Deductions Received By Cerecor ReturnDeductionsReceivedByCerecor
	aytu	Return Deductions Received By Cerecor ReturnDeductionsReceivedByCerecor	2000000
CY2021Q1	aytu	Return Reserve ReturnReserve	5592000
CY2020Q2	aytu	Return Reserve ReturnReserve	1329000
CY2020Q1	aytu	Stock Issued During Period Value Cashless Warrant Exercise StockIssuedDuringPeriodValueCashlessWarrantExercise
CY2021Q1	aytu	Stock Issued During Period Value Cashless Warrants Exercised StockIssuedDuringPeriodValueCashlessWarrantsExercised
CY2020Q1	aytu	Stock Issued During Period Value Cashless Warrants Exercised StockIssuedDuringPeriodValueCashlessWarrantsExercised	792
CY2020Q1	aytu	Stock Issued During Period Value Contingent Value Rights Payouts StockIssuedDuringPeriodValueContingentValueRightsPayouts	1732870
CY2021Q1	aytu	Stock Issued During Period Value Contingent Value Rights Payouts StockIssuedDuringPeriodValueContingentValueRightsPayouts	1000000
CY2020Q1	aytu	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	22989666
	aytu	Warrants Issued WarrantsIssued	1628293
	aytu	Warrants Issued WarrantsIssued
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001385818
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25170596
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16528646
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11824560
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28228434
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5632717
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43181920
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8645984
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	571000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	484000
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	302448362
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	215024216
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165171
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	162264
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	454918
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	508059
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1381429
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4523884
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	137735
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	101537
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4008866
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1272154
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1526000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	264000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2485000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	591000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-21916
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4900000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2900000
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1779881
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4471560
CY2021Q1	us-gaap	Assets Assets	271556601
CY2020Q2	us-gaap	Assets Assets	153293123
CY2021Q1	us-gaap	Assets Current AssetsCurrent	100012751
CY2020Q2	us-gaap	Assets Current AssetsCurrent	75422565
CY2021Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	171543850
CY2020Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	77870558
CY2021Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.41
CY2020Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-3.91
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-2.71
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-14.01
CY2020Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-13800554
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-31686745
CY2020Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	24824477
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	83141373
CY2021Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1536800
CY2020Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	311083
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2849037
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1533723
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-631298
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2680022
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4177282
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	713251
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16930682
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent
CY2021Q1	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-32674710
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-55711884
CY2021Q1	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	22250543
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	74582036
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	15721797
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	390916
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46537958
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48081715
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46800000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48333307
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11294227
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	46789953
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62516083
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1543354
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	51221856
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2288528
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1257525
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23457887
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12583736
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23457887
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12583736
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	2346
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	1259
CY2021Q1	us-gaap	Contractual Obligation ContractualObligation	35117000
CY2021Q1	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	3475000
CY2021Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	3300000
CY2021Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	1973000
CY2021Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	9769000
CY2021Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	8300000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	92880
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	13682297
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	1998659
	us-gaap	Cost Of Revenue CostOfRevenue	23499842
	us-gaap	Cost Of Revenue CostOfRevenue	2980425
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	39147946
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	12949616
	us-gaap	Costs And Expenses CostsAndExpenses	76947072
	us-gaap	Costs And Expenses CostsAndExpenses	27267247
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1057559
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68000
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10301150
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3780310
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
CY2020Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1830
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	1830
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.63
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14100000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9423000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8529000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2234500
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10510228
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3117177
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	307000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	339000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	117000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	88000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	105000
CY2021Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	29000
CY2021Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	32000
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2020Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y350D
CY2020Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1
CY2020Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	58473000
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	96236796
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	48854561
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-425425
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7591000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7825000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7981000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	93637000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P13Y204D
CY2020	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y40D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-112110
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	343185
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease
CY2021Q1	us-gaap	Goodwill Goodwill	65802636
CY2020Q2	us-gaap	Goodwill Goodwill	28090407
CY2021Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4286000
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	195000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6155583
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4912245
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1772274
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8183810
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5556614
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6761319
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3263723
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	271560
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4390470
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	345452
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6065996
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	358022
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1607170
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1611681
CY2021Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	114623000
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-538862
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1555924
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1181206
	us-gaap	Interest Paid Net InterestPaidNet	448603
	us-gaap	Interest Paid Net InterestPaidNet	392641
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10812000
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9603000
CY2021Q1	us-gaap	Inventory Net InventoryNet	16575757
CY2020Q2	us-gaap	Inventory Net InventoryNet	9999441
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2583000
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	397000
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3181000
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	7000000
	us-gaap	Inventory Write Down InventoryWriteDown	7227230
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	0
	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2021Q1	us-gaap	Lease Cost LeaseCost	96000
CY2020Q1	us-gaap	Lease Cost LeaseCost	27000
	us-gaap	Lease Cost LeaseCost	155000
	us-gaap	Lease Cost LeaseCost	72000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4291000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1154000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	557000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1117000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1182000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	281000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	508000
CY2021Q1	us-gaap	Liabilities Liabilities	128407088
CY2020Q2	us-gaap	Liabilities Liabilities	58277827
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	271556601
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153293123
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	83682981
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28763374
CY2021Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4738825
CY2020Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent
CY2021Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	150000
CY2020Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	315000
CY2021Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	10726691
CY2020Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	12874351
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18498572
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77441786
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-364094
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5610732
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19700000
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20600000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19677832
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20609198
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4929030
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-214247
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5332305
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4305931
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9525294
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-25459791
	us-gaap	Net Income Loss NetIncomeLoss	-39291016
	us-gaap	Net Income Loss NetIncomeLoss	-10475582
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	104321912
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	88699892
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	205873
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-538862
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4493505
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4020430
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent
CY2020Q2	us-gaap	Notes Payable Current NotesPayableCurrent	982076
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25665664
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4793443
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34797511
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14496012
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3783000
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	910885
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	300426
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2871845
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	725374
	us-gaap	Operating Lease Payments OperatingLeasePayments	128000
	us-gaap	Operating Lease Payments OperatingLeasePayments	72000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3781737
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	634093
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0662
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0809
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y244D
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y120D
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404000
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	588000
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1615024
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	5742011
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	164954
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	32981
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	92894
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11371
CY2021Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1998012
CY2020Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	2340166
CY2021Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	9422768
CY2020Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	11171491
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	683241
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	151648
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4430516
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5280426
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15398727
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5850000
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6803583
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5715089
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;margin:0pt;"><div style="display: inline; font-weight: bold;">Reclassification</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;text-align:justify;margin:0pt;text-indent:18pt;">The Company historically presented accrued distributor fees as a reduction to accounts receivable. However, beginning this quarterly report and for the comparative periods presented, accrued distributors fees will be presented in accrued liabilities instead of accounts receivable. As of <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>accrued distributor fees included in accounts receivable, net on the balance sheet was <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$457,000</div>.</div> This reclassification will have <div style="display: inline; font-style: italic; font: inherit;">no</div> impact on the Company's statements of operation and cash flows presented in this quarterly report.</div></div></div></div></div></div></div></div></div></div></div></div></div>
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	640000
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	32249652
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	58999666
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22989666
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5557727
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	258516
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	335036
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts
	us-gaap	Repayments Of Debt RepaymentsOfDebt	318181
	us-gaap	Repayments Of Debt RepaymentsOfDebt
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5968290
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	389262
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78502
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	858698
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	223197
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	251995
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	251592
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	4818064
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges
	us-gaap	Restructuring Charges RestructuringCharges	4874723
	us-gaap	Restructuring Charges RestructuringCharges	135981
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159301195
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120010179
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13482282
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	42149561
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8156173
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12771235
CY2021Q1	us-gaap	Revenues Revenues	13482000
CY2020Q1	us-gaap	Revenues Revenues	8156000
	us-gaap	Revenues Revenues	42150000
	us-gaap	Revenues Revenues	12771000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	66182
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	354929
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.14
CY2021Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	725357
CY2020Q2	us-gaap	Secured Debt Current SecuredDebtCurrent
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12851087
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9190386
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35825175
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19494368
	us-gaap	Share Based Compensation ShareBasedCompensation	2485330
	us-gaap	Share Based Compensation ShareBasedCompensation	590826
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20569
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	87.86
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2528
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7553
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	69721
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76614
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	136254
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.39
CY2019Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y204D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y244D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y43D
CY2019Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5559914
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4406184
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	53102918
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	92880
CY2020Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1057559
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	33278756
CY2020Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28317444
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	263391
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	7087818
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2323959
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17090240
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	85703816
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	95015296
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	91062746
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	112692668
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	143149513
CY2021Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	182000
CY2020Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	175000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman"; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent consideration, contingent value rights ("CVRs"), and fixed payment obligations at the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, those related to the determination of the fair value of equity awards, the fair value of identified assets and liabilities acquired in business combinations, net realizable value of inventory, the useful lives of property and equipment, intangible assets, impairment of long-lived and intangible assets, including goodwill, provisions for doubtful accounts receivable, certain accrued expenses, and the discount rate used in measuring lease liabilities. These estimates and assumptions are based on the Company's historical results and management's future expectations. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18092465
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3527530
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14490219
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2261697

Files In Submission

Name	View Source	Status
0001437749-21-012543-index-headers.html	Edgar Link	pending
0001437749-21-012543-index.html	Edgar Link	pending
0001437749-21-012543.txt	Edgar Link	pending
0001437749-21-012543-xbrl.zip	Edgar Link	pending
aytu-20210331.xml	Edgar Link	completed
aytu-20210331.xsd	Edgar Link	pending
aytu-20210331_cal.xml	Edgar Link	unprocessable
aytu-20210331_def.xml	Edgar Link	unprocessable
aytu-20210331_lab.xml	Edgar Link	unprocessable
aytu-20210331_pre.xml	Edgar Link	unprocessable
aytu-logorgbsmallersize428.jpg	Edgar Link	pending
aytu20210329_10q.htm	Edgar Link	pending
brookesig.jpg	Edgar Link	pending
cb1.jpg	Edgar Link	pending
cm02.jpg	Edgar Link	pending
cmbrookesig.jpg	Edgar Link	pending
doublesig.jpg	Edgar Link	pending
ex_237789.htm	Edgar Link	pending
ex_237790.htm	Edgar Link	pending
ex_237791.htm	Edgar Link	pending
ex_249025.htm	Edgar Link	pending
ex_249025img001.jpg	Edgar Link	pending
ex_249025img002.jpg	Edgar Link	pending
ex_249026.htm	Edgar Link	pending
ex_249026img001.jpg	Edgar Link	pending
ex_249026img002.jpg	Edgar Link	pending
ex_249027.htm	Edgar Link	pending
ex_249027img001.jpg	Edgar Link	pending
ex_249027img002.jpg	Edgar Link	pending
ex_249028.htm	Edgar Link	pending
ex_249028img001.jpg	Edgar Link	pending
ex_249028img002.jpg	Edgar Link	pending
ex_249029.htm	Edgar Link	pending
ex_249029img001.jpg	Edgar Link	pending
ex_249110.htm	Edgar Link	pending
ex_249111.htm	Edgar Link	pending
ex_249111img001.jpg	Edgar Link	pending
ex_249111img002.jpg	Edgar Link	pending
ex_249112.htm	Edgar Link	pending
ex_249112img002.jpg	Edgar Link	pending
ex_249686.htm	Edgar Link	pending
ex_250530.htm	Edgar Link	pending
ex_250530img001.jpg	Edgar Link	pending
ex_250530img002.jpg	Edgar Link	pending
ex_250530img003.jpg	Edgar Link	pending
ex_250530img004.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
luosig.jpg	Edgar Link	pending
nm01.jpg	Edgar Link	pending
r01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slsig.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AYTU
AYTU BIOPHARMA, INC Stock $aytu

2021 Q2 Form 10-Q Financial Statement

#000143774921012543 Filed on May 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU AYTU BIOPHARMA, INC Stock $aytu

2021 Q2 Form 10-Q Financial Statement

#000143774921012543 Filed on May 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU
AYTU BIOPHARMA, INC Stock $aytu